Patency of autologous human saphenous vein coronary artery bypass grafts (CABG) is compromised by intimal thickening and superimposed atherosclerosis, caused by migration of vascular smooth muscle cells (SMC) to the intima where they proliferate. Here, using adenoviral transfer, we have targeted SMCs using wild-type p53 (wt p53) overexpression. Initial in vitro analyses demonstrated that wt p53 overexpression had no effect on SMC proliferation but promoted apoptosis, which was inhibited by co-expression of bcl2 or crmA. Wt p53 inhibited SMC invasion through reconstituted matrices, a phenotype not affected by bcl2 or crmA. Overexpression of wt p53 in human saphenous vein
Introduction
Saphenous vein is the most commonly used conduit for coronary artery bypass grafts. 1 Although over 400 000 saphenous vein bypass grafts are carried out each year in the USA, 2 this procedure has an unacceptably high failure rate and approximately 50% of vein grafts become occluded within 10 years. 3 Early occlusions, which occur in the first year, are caused by thrombosis and account for approximately 10% of the failures. The remainder of the grafts fail later on due to intimal thickening and superimposed atherosclerosis. 4 The intimal thickening that occurs after placing the vein into the arterial circulation, is due to the accumulation of smooth muscle cells (SMCs) and deposition of extracellular matrix in the intima. 5 Accumulation of SMCs in the intima is due to the migration of SMCs from the media to the intima where they subsequently proliferate.
Recently, it has become apparent that genetic modification of the vessel wall may be useful in the clinic. This procedure is particularly suited to gene therapeutics due to the access to material ex vivo before grafting into the arterial circulation, thus enhancing the safety profile of before organ culture significantly induced apoptosis (P Ͻ 0.01, Student's t test) without affecting proliferation rates either in the media or in the intima. SMC migration was, however, significantly reduced by wt p53 (P Ͻ 0.01, Student's t test). Intimal thickening and the number of neointimal cells were reduced by 89% and 73%, respectively, after 14 days (P Ͻ 0.01 and P Ͻ 0.001, respectively, Student's t test). This study demonstrates that overexpression of wt p53 promotes apoptosis and inhibits migration of SMC leading to reduced intimal thickening. This maybe a useful approach for increasing patency rates in CABG procedures in the clinic. Gene Therapy (2001) 8, 668-676. potential therapies. 6 To date, a number of studies have targeted different mechanisms involved in the progression of vein graft neointimal thickening, [7] [8] [9] [10] [11] [12] [13] and recently, clinical trials have been initiated. 14 Mann et al 10, 11 modulated the cell cycle using antisense oligonucleotides targeting proliferating cell nuclear antigen (PCNA) or cell division cycle 2 (cdc 2) kinase, and reduced neointimal hyperplasia 10 through enhanced nitric oxide bioavailabilty and reduced monocyte adhesion and vascular cell adhesion molecule-1 (VCAM-1) expression.
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Our previous studies in human and pig models of vein graft neointimal thickening have highlighted the potential benefit of matrix metalloproteinase (MMP) inhibition in prevention of vein graft neointimal hyperplasia. 8, 9, 13, 15 In particular, we demonstrated that inhibition of SMC migration by MMP combined with induction of SMC apoptosis by TIMP-3 overexpression was beneficial in human and pig models. 13 Other pro-death strategies have demonstrated efficacy in post-angioplasty restenosis models by overexpression of thymidine kinase. [16] [17] [18] Wildtype p53 (wt p53) has been shown to promote SMC apoptosis 19 and modulate SMC proliferation, 20 phenotypes that may be beneficial for prevention of neointimal hyperplasia by gene therapy. In this study we document the effect of wt p53 overexpression on human saphenous vein SMC in isolated culture and in an organ culture model of human vein graft neointimal thickening.
Results
Adenoviral vectors mediate high-level overexpression of wt p53 in isolated human saphenous vein SMC To define the effect of p53 overexpression on isolated human saphenous vein SMC we overexpressed wt p53 in low passage cell cultures. Uninfected SMC or cells infected with up to 1000 p.f.u. per cell RAdlacZ demonstrated no nuclear staining with anti-wt p53 antisera (Figure 1a, b) . In direct contrast, RAdp53 mediated highlevel nuclear overexpression of wt p53 in infected SMC (Figure 1c) , with no staining in isotype-matched nonimmune anti-sera (Figure 1d ). Western blot analysis of cells harvested at 42 h after infection confirmed p53 overexpression with RAdp53, but not in uninfected or RAdlacZ-infected cells (Figure 1e ).
Wt p53 induces apoptosis and inhibits SMC invasion
We examined the effect of wt p53 on proliferation of SMCs using a number of independent techniques ( Figure  2 ). No significant effect of p53 overexpression was observed between wt p53 overexpressing cells compared with uninfected control or RAdlacZ-infected cells at any MOI tested (up to 1000 p.f.u. per cell) (Figure 2a-c) . We also estimated cell number by quantification of total DNA/well and demonstrated no significant difference at any MOI tested (data not shown). In addition, FACS analysis of cells demonstrated that the cell cycle characteristics of SMC were unaffected by p53 overexpression compared with RAdlacZ-infected controls at any MOI (data not shown). In support of these findings we observed, using Western blot analysis, that the levels of the cell cycle inhibitor p21(WAF1) were not significantly altered by overexpression of wt p53 (Figure 2d , e).
We next defined the effect of wt p53 overexpression on SMC apoptosis assessed by microscopy and in situ end labelling (ISEL Gene Therapy typical features of apoptosis including membrane blebbing and chromatin condensation in SMC infected with RAdp53 but not uninfected with RAdlacZ-infected control cultures (Figure 3a-c) . ISEL confirmed apoptotic cell death with intense staining indicating DNA fragmentation in the nuclei of RAdp53-infected SMC (Figure 3d f). Quantification of ISEL revealed that, as expected, basal levels of ISEL were low in uninfected SMC (Ϸ1.5%) with no significant effect observed in RAdlacZ-infected cultures even at a MOI of 1000 p.f.u. per cell (Figure 3g ). However, wt p53 resulted in a significant increase in ISEL-positive SMCs at all MOI of RAdp53 tested ( Figure  3g ). In separate experiments we co-overexpressed wt p53 and either bcl2 or crmA. Both RAdbcl2 and RAdcrmA reduced apoptosis induced by p53 back to basal levels ( Figure 4h ). Due to the fundamental role of SMC migration in the progression of intimal thickening, we defined the effect of wt p53 overexpression on invasion through reconstituted basement membranes (Matrigel). We observed that wt p53 significantly reduced SMC invasion compared with both uninfected controls and RAdlacZ-infected cultures at all MOI tested (Figure 4a ). Wt p53 was, in fact, as efficient as the metalloproteinase (MMP) inhibitor TIMP-2 at reducing invasion ( Figure 4a) . Interestingly, the level of inhibition of invasion was far greater than the level of apoptosis. We again examined whether bcl2 or crmA co-overexpression inhibited this phenotype. In direct contrast to apoptosis, neither bcl2 nor crmA affected the inhibition of invasion mediated by wt p53 (Figure 4b ).
Evaluation of wt p53 overexpression in human saphenous vein
Following local adenoviral delivery to the lumenal surface, immunocytochemistry was used to evaluate the levels of endogenous and adenoviral-induced wt p53 expression in human saphenous vein sections 4, 7 and 14
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Figure 2 Effect of wt p53 overexpression on proliferation of SMC cultures. (a) MTT assay for SMC proliferation at 42, 66 and 90 h after initiation of infection at increasing MOI of RAdp53 and RAdlacZ. Data are presented as the absorbance (Abs) at 450 nm. (b) 3 H-thymidine incorporation assay in uninfected and infected SMC analysed 66 h after initiation of infection. Data are expressed as a percentage of uninfected control SMC (UN) at each time-point. (c) Total cell counts 42 and 66 h after infection. (d) Representative Western blot for p21(WAF1) expression in uninfected (UN), RAdp53-and RadlacZ-infected cells with increasing MOI. (e) Densitometric scanning analysis of p21 expression from three independent Western blots, each loaded equally for protein.
days after infection. p53 was undetectable in uninfected vein segments (Figure 5a-c) and vein segments infected with RAdlacZ at any time-point (not shown). However, wt p53 was abundant in RAdp53 infected veins ( Figure  5d -f). Quantification revealed that wt p53 was detected in 19 ± 5, 23 ± 8 and 23 ± 6% of lumenal surface cells (defined as less than 5 m from the lumenal surface) in the vein segments infected with the RAdp53 at 4, 7 and 14 days, respectively, consistent with the level of infection achieved with other adenoviruses. 9 The cells expressing recombinant p53 were located at the lumenal surface of the media, again consistent with distribution patterns of recombinant protein following lumenal-specific delivery with adenoviral vectors. 9 Effect of wt p53 overexpression SMC migration, proliferation and apoptosis in organ cultures Consistent with observations in isolated cells, infection of human saphenous vein with RAdp53 did not affect SMC proliferation in the medial layer. However, intimal cell proliferation, assessed by continuous bromodeoyuridine (BrdU) labelling, was reduced in infected vein segments after 4 days of culture (Table 1) , although there was no significant difference at other time-points (Table 1) . No correlation between the number of cells expressing p53 and SMC proliferation were observed (Table 2) . However, we observed that the number of migrating cells (ie those cells that arose in the neointima by migration alone and were therefore BrdU-negative) was significantly reduced by RAdp53 infection at all time-points (Table 1) . Furthermore, the number of cells expressing p53 was negatively correlated with the reduction in migration (Table 2) . ISEL revealed that apoptosis was significantly increased in vein segments infected with RAdp53 after 4 and 7 days of culture (Table 3, Figure 6 ) and the number of cells positive for p53 positively correlated with medial apoptosis (Table 3 ). The correlation was present for both medial and intimal apoptosis. Apoptosis was not affected in the intima (Table 3, Figure 6 ). Although the density of SMCs in the media was not significantly affected by infection with RAdp53 (Table 3) , the density of SMCs was negatively correlated with p53 expression (Table 2) .
Wt p53 overexpression inhibits neointimal thickening
Infection with RAdp53 significantly reduced intimal thickness by 89%, after 14 days of culture, compared with uninfected controls (Table 1, Figure 7 ). The total number of intimal cells was significantly reduced by 74% on day 7 and 73% on day 14 after infection (Table 1) . Furthermore, the total number of intimal cells was negatively correlated with the percentage of lumenal cells expressing p53 protein (Table 2 ). Since the number of intimal cells and the intimal area were both reduced by infection with RAdp53, the density of neointimal cells/m 2 was not affected by RAdp53 infection (Table 1) .
Discussion
The ability to elevate patency rates in saphenous vein bypass procedures has tremendous potential to improve patient care and relieve economic burden on society. In this study we have identified that the tumour suppressor gene wt p53 induces phenotypic changes to SMC from saphenous vein that are promising as a gene therapy approach for CABG. In particular, we found that in saphenous vein SMC, p53 was able to inhibit migration and promote apoptosis of SMC leading to significantly fewer intimal cells and hence a profound reduction in neointimal lesions.
Wild-type p53 gene overexpression, even to very high levels of gene transfer, had no effect on human saphenous vein SMC proliferation analysed by two independent techniques, and by lack of induction of p21. This was surprising as other studies have shown the involvement of p53 in SMC proliferation. In bovine SMC, wt p53 gene transfer using the hemagglutinating virus of Japan/liposome method efficiently inhibited plateletderived growth factor (PDGF)-induced induction of proliferation in vitro and in vivo through synthetic phase depletion. 20 In our study we addressed proliferation status in the presence of serum, not PDGF alone, as ultimately, genetically modified vein grafts will be exposed to the complex array of growth modulating agents and survival agents present in serum. Thus it may be possible for wt p53 to modify SMC growth to certain stimuli (such as PDGF), but not to others. Aoki et al 21 demonstrated that in human aortic SMC down-regulation of p53 using antisense leads to SMC proliferation. Elegantly, it was also demonstrated that antisense-mediated down-regulation of the retinoblastoma gene led to SMC apoptosis which was efficiently inhibited in the absence of p53 protein providing direct evidence for the role of p53 in vascular SMC apoptosis. 21 Furthermore, in another study using human aortic SMC, overexpression of p53 was 200 times more pro-apoptotic than an adenovirus expressing p21. 19 Thus, it remains possible that human SMC derived from saphenous vein are more resistant to the growth inhibitory properties of p53 than arterial SMC, possibly through reduced susceptibility to growth inhibition, but not to apoptosis. In support of this, evidence for independent pathways regulating SMC proliferation and apoptosis in response to p53 has been documented by Bennett et al. 22 There is clear evidence for the activation of multiple p53-sensitive pathways following gene transfer to SMC as demonstrated by our co-overexpression studies. The effect of p53 on migration cannot be accounted for by the effect of p53 overexpression on apoptosis alone, as the inhibition of migration was much higher than the level of apoptosis during the same 24 h time-period. While, as expected, the anti-apoptotic proteins bcl2 and crmA blocked wt p53-mediated apoptosis of SMC, these agents had no effect on the inhibition of SMC invasion through reconstituted basement membranes. Clearly, further studies are required to elucidate the mechanism(s) by which wt p53 overexpression inhibits invasion. It may be possible that wt p53 inhibits matrix metalloproteinases (MMPs), as has been described for melanoma cells. Increased expression of wt p53 significantly reduced intimal thickening and the number of intimal cells. Intimal thickening in the human saphenous vein organ culture model has been shown to depend on both migration and proliferation of SMC. 24 SMC migration to the intima as estimated by number of cells negative for BrdU in the intima was significantly reduced in the wt p53 infected vein types, consistent with the findings in Boyden chamber experiments.
Figure 3 Evaluation of wt p53-mediated apoptosis. (a-c) Phase contrast microscopy to visualise morphological features of apoptosis 42 h after infection, in (a) uninfected, (b) RAdlacZ-infected and (c) RAdp53-infected SMC infected at 100 p.f.u. per cell. (d-f) ISEL analysis 42 h after infection of isolated SMC cultures 42 h after infection, in (d) uninfected, (e) RadlacZ-infected and (f)
Radp53
Figure 5 Immunocytochemical detection of p53. Immunoreactive p53 was localised in HSV segments by immunocytochemistry at days 4, 7 and 14 after infection. (a-c) uninfected HSV at days 4, 7 and 14, respectively; (d-f) RAdp53-infected HSV at days 4, 7 and 14, respectively. Large arrows in (b) and (c) indicate intimal medial boundary and small arrows in (d), (e) and (f) indicate cells with p53 immunoreactivity. The scale bar in (a) represents 25 m and is applicable to all panels.
In summary, this study demonstrates that over expression of wt p53 in saphenous vein SMC promotes apoptosis, but also inhibits invasion, in part through modulation of pro-MMP-2 levels. In organ cultures, wt p53 mimics these effects resulting in a profound reduction in intimal thickening. Wt p53 overexpression may therefore be a useful strategy for gene therapy aimed at elevating patency rates in human bypass grafts.
Materials and methods

Materials
All reagents were purchased from Sigma (Poole, UK) except for those below. l-glutamine, penicillin-strepto- 
Figure 6 Effect of RAdp53 infection on apoptosis in human saphenous vein segments. Representative ISEL of sections of HSV stained to illustrate apoptosis at days 4 (a and d), 7 (b and e) and 14 after infection (c and f). (a-c) uninfected HSV and (d-f) RAdp53-infected vein. The large arrows in (b) and (c) indicate the neointima media boundary and the small arrows in (d), (e) and (f) indicate ISEL-positive cells. The scale bar in (a) represents 25 m and is applicable to all panels.
Figure 7 Effect of RAdp53 infection on intimal thickening. Representative sections stained with EVG to highlight neointima formation at days 1 (A and D), 7 (B and E) and 14 after infection (C and F). (A-C) uninfected HSV and (D-F) RAdp53-infected vein. The arrows indicate the neointima media boundary. The scale bar in (A) represents 25 m and is applicable to all panels.
mycin and culture media were obtained from Gibco BRL (Paisley, UK), amphotericin from McCarthy Medical (Wrexham, UK) and gentamycin from Roussel (Uxbridge, UK). The monoclonal anti-human p53 and p21 antibodies were purchased from Oncogene Research Products
Gene Therapy (Cambridge, UK) and the monoclonal anti-bromodeoxyuridine antibody was obtained from ICN Pharmaceuticals (Rickmansworth, UK). DNA polymerase I (Klenow fragment) was obtained from Promega (Southampton, UK). ATP, CTP and GTP and biotin-UTP were from Roche Molecular Biochemicals (Lewes, UK). Biotinylated anti-mouse and anti-rabbit secondary antibodies were purchased from DAKO (High Wycombe, UK).
Recombinant adenoviruses
All adenoviral constructs used were first generation E1a-negative replication-defective recombinant adenoviruses. RAdp53 is a replication-defective recombinant adenovirus containing the cDNA for human wt p53 driven by the cytomegalovirus promoter and has been described previously. 25, 26 RAdlacZ expresses lacZ 27 and RAdTIMP-2 expresses the human TIMP-2 gene from the CMVIEP.
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RAdbcl2 and RAdcrmA contain the cDNA for bcl2 and crmA, respectively. Adenoviral stocks were banded on caesium chloride gradients, extensively dialysed and stored at −70°C, before use. Lack of replication-competent adenovirus was determined by titration on non-permissive Hela cells and lack of E1a by immunofluorescence using an anti-E1a monoclonal antibody (Calbiochem, Cambridge, UK).
SMC isolation and adenoviral infection
Human saphenous vein SMCs were isolated from saphenous vein segments using the explant technique 29 and maintained in Dulbecco's modified Eagle's medium containing 4500 mg/l glucose, 10% fetal calf serum and antibiotics (complete media). Cells were utilised between passages 2 and 6. Cells were infected at Ϸ70% confluency. An accurate cell count was performed before infection. Cells were infected with increasing MOI of adenovirus for 18 h in complete media. Cells were subsequently washed and maintained in complete media until the required time-point unless otherwise stated.
Immunofluorscence SMC were sub-cultured on to glass coverslips and infected with adenoviruses for 18 h, washed and left for a further 24 h. Cells were washed in PBS, fixed in icecold methanol for 10 min. Cells were incubated with 1 g/ml anti-p53 antibody (Calbiochem) in PBS containing 10% goat serum or isotype-matched control non-immune sera. Wt p53 staining was visualised with biotinylated goat anti-mouse immunoglobulin G (DAKO) and fluorescein (FITC)-conjugated Extravidin.
Western blot analysis
Control uninfected and adenovirus infected cells were harvested 66 h after initiation of infection. Samples were electrophoresed through 3-8% gradient polyacrylamide gels (NOVEX, Lichfield, UK) for wt p53 or 12% polyacylamide gels for p21 and blotted on to nitrocellulose membranes (NOVEX). Membranes were blocked in tris-buffered saline (TBS) containing 5% (w/v) non-fat skimmed milk and 0.1% (v/v) tween 20 for 1 h and then incubated overnight with 1 g/ml of mouse anti-human p53 antibody (Calbiochem) and 2 mg/ml of mouse anti-human p21 antibody (Pharmingen, Oxford, UK) in TBS containing 5% (w/v) non-fat skimmed milk and detected using enhanced chemiluminescence (ECL, Amersham International, Little Chalfont, UK).
Proliferation studies SMC were infected with increasing MOI of each adenovirus for 18 h, cells washed and analysed by the water soluble tetrazolium (WST) assay at 42, 66 and 90 h after initiation of infection. In brief, WST reagent (Roche Molecular Biochemicals) was added to cells, left for 2 h and the absorbance at 450 nm measured. We also performed 3 H-thymidine incorporation studies. At 42 h after initiation of infection, SMC were incubated for 24 h with 1 Ci/ml 3 H-thymidine. Cells were extracted using 10% TCA as described 24 Boyden chamber assays For evaluation of invasion through reconstituted basement membrane, SMC were infected for 18 h with increasing MOI of control (RAdlacZ), or test (RAdp53) adenovirus. Cells were washed following infection and left in complete media for a further 24 h to allow sufficient time for gene expression to occur. Cells were trypsinised, resuspended in DMEM without phenol red containing 1% BSA, counted. 5 × 10 4 cells per well were placed on the upper side of chambers coated with 0.75 mg/cm 2 Matrigel (Becton Dickinson Labware, Bedford, UK). Chemoattractant (10% FCS in DMEM without phenol red containing 1% BSA) was placed in the lower chamber and left for 24 h at 37°C. Cells that had invaded on to the underside of the filter were counted following staining with haematoxylin. Six wells were performed per condition and six high power fields counted per well. For co-overexpression studies cells were infected with 150 p.f.u. per cell of each adenovirus under test.
Infection of human saphenous vein
Segments of surgically prepared human saphenous vein (n = 6), not required for surgery were collected from patients after the completion of the coronary artery bypass surgery, as described previously. 24, 30 The vein segment was placed in wash medium (20 mm Hepes-buffered RPMI 1640 supplemented with 2 mm l-glutamine, 8 g/ml gentamycin, 100 IU/ml penicillin and 100 g/ml streptomycin). After removal of the adventitial layer, the vein was bisected transversely. One segment was infected with RAdp53 while the other segment was used as a paired uninfected control. The vein was infused with 100 l of 1.2 × 10 10 p.f.u./ml RAdp53 or RAdlacZ as described previously 9 for a period of 1 h. Both infected and control segments were then opened longitudinally and cut transversely into three 5-10 mm segments. Vein segments were cultured separately endothelial surface uppermost for up to 14 days in culture medium (RPMI 1640 supplemented with 30% fetal calf serum (FCS), 2 mm l-glutamine, 100 IU/ml penicillin, 100 g/ml strep-tomycin and 10 m BrdU, using a modification of the organ culture method of Pederson and Bowyer as described. 31 The tissue culture medium was changed every 2 days. After 4, 7 or 14 days of culture the vein segments were washed in PBS and then fixed in 10% (v/v) formalin in PBS.
Immunocytochemical techniques
For evaluation of wt p53 expression, after embedding in paraffin wax, 3 m sections were cut and used for immunocytochemical analysis of p53, using a monoclonal antihuman p53 antibody. Briefly, after dewaxing and dehydrating, antigens retrieval was carried out by incubating with 5 g/ml proteinase K for 15 min at room temperature. The sections were then incubated in 20% (v/v) goat serum for 30 min before incubation with the monoclonal anti-p53 antibody at 1 g/ml in 1% (w/v) bovine serum albumin (BSA) in PBS for 1 h. After incubation with biotinylated goat anti-mouse IgG antibodies and Extravidinhorseradish peroxidase diluted 1:200 in 1% (w/v) BSA in PBS, sections were incubated with 3,3Ј-diaminobenzidine. All slides were counter stained with haematoxylin.
Cell proliferation was assessed by immunocytochemistry for incorporated BrdU, using a monoclonal anti-BrdU antibody. Immunocytochemistry was carried out in a similar manner as that described for p53, although trypsin digestion was used for antigen retrieval. Nuclei were counterstained with haematoxylin and the BrdU index quantified in six high power fields per section. SMC migration was estimated by counting the number of cells in the intima that are not labelled with BrdU and dividing by the length of the vein segment. This method defines cells present within the intima that have arisen by migration alone, and not by migration and proliferation.
Apoptosis was determined by in situ end labelling (ISEL) as described. 9 The density of SMCs in the medial layer was also calculated.
Quantification of intimal thickening
Transverse sections (3 m) were stained with Miller's elastic van Gieson (EVG) and Mayer's haematoxylin and eosin staining and the intimal thickening quantified using the Media Cybernetics Image Pro Plus version 3 image analysis system (Data Cell, Maidenhead, UK). Briefly, the intimal area and length of the vein segment were measured. The mean intimal thickness was determined by dividing the intimal area by the length of the vein segment. The number of intimal cells at 4, 7 and 14 days were counted on two non-serial sections, the mean calculated for each vein and divided by the length of the section (in mm) to normalise for vein diameter variations between patients.
Statistical analysis
Analysis was performed using ANOVA for multiple comparisons between groups and where data was significant paired Student's t tests were performed to test for significance between the two groups. For in vitro analyses statistical significance was only assigned for RAdp53-infected samples when significantly different from both uninfected and RAdlacZ-infected cells. Correlation of the number of cells expressing wt p53 with the other parameters measured was tested using Pearson linear correlation. Statistical significance was accepted when P Ͻ 0.05.
